Elevated myostatin is linked to muscle wasting, frailty, and conditions such as obesity, COPD, sepsis, and sarcopenia and is considered a potential biomarker for muscle impairment and rehabilitation needs [102,103]. Here, MSTN is linked to sarcopenia.